Form D · Other
Allinaire Therapeutics Inc.
Cleveland, OH · CIK 0002113399
Offering snapshot reported Apr 14, 2026 · SEC filing
- Reported sold
- $700K Offering amount: $700K
- Investors reported
- 2 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Jan 30, 2026 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Apr 14, 2026 | Initial | $700,000 | No comparison | 2 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-580441
Source: Form D, filed Apr 14, 2026. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Arthur Bertelson | Director |
| Samantha Ginther | Director |
| Douglas W.P. Hay | Director, Executive |
| Satish Jindal | Director |
Issuer details
Industry: Other (See others in industry)
Address:
11000 Cedar Ave #18
Cleveland, OH, 44106
Cleveland, OH, 44106